InsidersTradesSigma
Total declarations
Companies
▲ Purchases (7 ops.)
▼ Sales (1 ops.)
Insider track record
Board DirectorDisclosed buys
7
Disclosed sells
1
T+90 hit rate
0%
T+90 mean return
-23.0%
Across 8 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by PACE GARY W, Director. Insider active across 2 companies, notably Pacira BioSciences, Inc.. Aggregated, 15 disclosures have been recorded. Split: 7 buys · 1 sell. Total volume traded: €1.6m. Activity tracked since 13 May 2021. The latest transaction was disclosed on 11 December 2024 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations15 total
30,000 sharesCommon StockSEC:0001184778-26-000009:0
Ideal exit: 15 Mar 2027 (T+270)
350,115 shares@ US$2.6056.7% of flowCommon StockSEC:0000950170-24-135767:0
Ideal exit: 7 Sept 2025 (T+270)
1,066 shares@ US$29.677.6% of flowCommon StockSEC:0001396814-24-000037:0
30,000 shares@ US$1.372.5% of flowCommon StockSEC:0001628280-23-042045:0
Ideal exit: 14 Sept 2024 (T+270)
22,950 shares@ US$0.981.4% of flowCommon StockSEC:0001628280-23-038955:0
Ideal exit: 6 Aug 2024 (T+270)
1,775 shares0Common StockSEC:0001209191-23-038025:0
7,000 shares@ US$29.9049.7% of flowCommon StockSEC:0001209191-23-029616:0
150,000 shares@ US$1.7116.8% of flowCommon StockSEC:0001628280-22-025100:0
Ideal exit: 12 Jun 2023 (T+270)
1,160 shares0Common StockSEC:0001209191-22-035227:0
7,000 shares@ US$10.810.0064% mcap41.3% of flowCommon StockSEC:0001209191-22-016876:0
9,807 shares@ US$11.020.0091% mcap58.7% of flowCommon StockSEC:0001209191-22-014267:0
30,000 shares@ US$6.750.15% mcap50.0% of flowCommon StockSEC:0001628280-21-019057:0
Ideal exit: 18 Jun 2022 (T+270)
30,000 shares@ US$6.7511.3% of flowCommon StockSEC:0001628280-21-019057
Ideal exit: 18 Jun 2022 (T+270)
1,485 shares0Common StockSEC:0001209191-21-040097
1,485 shares0Common StockSEC:0001209191-21-040097:0
15 of 15 declarations
About PACE GARY W
Gary W Pace is a Board Member at Pacira BioSciences, Inc. and Cardiff Oncology, Inc. He is involved in overseeing operations and development strategy for both companies. His expertise in the biopharmaceutical field is an asset to the board.
